HCWB Insider Trading (HCW Biologics)

Insider Ownership Percentage: 44.00%
Insider Buying (Last 12 Months): $62,126.68
Insider Selling (Last 12 Months): $0.00

HCW Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at HCW Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HCW Biologics Share Price & Price History

Current Price: $2.26
Price Change: Price Increase of +0.03 (1.35%)
As of 08/16/2022 01:00 AM ET

This chart shows the closing price history over time for HCWB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

HCW Biologics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/13/2022Rebecca ByamCFOBuy7,596$2.08$15,799.6896,596View SEC Filing Icon  
6/10/2022Gary M WinerDirectorBuy1,500$2.13$3,195.0013,000View SEC Filing Icon  
6/9/2022Hing C WongCEOBuy2,000$2.25$4,500.0015,284,948View SEC Filing Icon  
6/8/2022Gary M WinerDirectorBuy1,000$2.27$2,270.0010,500View SEC Filing Icon  
6/6/2022Gary M WinerDirectorBuy1,000$2.13$2,130.008,500View SEC Filing Icon  
6/2/2022Rick S GreeneDirectorBuy4,800$2.09$10,032.008,411View SEC Filing Icon  
12/6/2021Jin-An JiaoVPBuy10,000$2.42$24,200.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for HCW Biologics (NASDAQ:HCWB)

1.03% of HCW Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HCW Biologics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/12/2022BlackRock Inc.39,583$0.11M0.0%+136.8%0.111%Search for SEC Filing on Google Icon
5/12/2022HighTower Advisors LLC215,598$0.59M0.0%+2,056.0%0.602%Search for SEC Filing on Google Icon
11/15/2021HighTower Advisors LLC14,000$45K0.0%N/A0.039%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
HCW Biologics logo
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Read More on HCW Biologics

Today's Range

Now: $2.26
Low: $2.25
High: $2.32

50 Day Range

MA: $2.28
Low: $1.97
High: $2.67

52 Week Range

Now: $2.26
Low: $1.76
High: $7.05

Volume

9,406 shs

Average Volume

9,381 shs

Market Capitalization

$80.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of HCW Biologics?

HCW Biologics' top insider investors include:
  1. Hing C Wong (CEO)
  2. Rebecca Byam (CFO)
  3. Gary M Winer (Director)
  4. Rick S Greene (Director)
  5. Jin-An Jiao (VP)
Learn More about top insider investors at HCW Biologics.